DPP-4 inhibition & vascular repair – mobilization endogenous stem cells

DPP-4 inhibitors and the study of ancillary effects is gaining an increasing interest for the possible cardiovascular benefit of these drugs beyond glucose control. As DPP-4 inhibitors show favorable safety profiles and do not cause hypoglycemia, they are attractive drugs also for non-diabetic patients and may become part of a vascular regenerative pharmacotherapy (Atherosclerosis)